Table 3.
Univariate analysis of patents divided into the response and non-response groups
| Response group | Non-response group | p-value | |
|---|---|---|---|
| Age, years; median (range) | 67 (35–89) | 64 (24–77) | 0.21 |
| Sex (Male: Female) | 60:45 | 18:8 | 0.18 |
| Primary site (Lungs: GU tract: GI tract: Breasts: HN: Thyroid: Gyne: Unknown) | 27:26:29:5:4:4:4:6 | 8:8:5:1:1:0:0:3 | 0.69 |
| Histology (SCC: Adeno: Small: CC: Others: Unknown) | 5:53:4:17:24:2 | 4:13:0:5:3:1 | 0.27 |
| Metastases site (Vertebral or non-vertebral) | 67:38 | 19:7 | 0.57 |
| Bone metastases type (Osteolytic: Osteoblastic: Mixed) | 72:25:8 | 16:9:1 | 0.47 |
| Pathological fracture (Present: Absent) | 17:88 | 7:19 | 0.21 |
| MRI | 43 (41%) | 11 (42%) | 0.54 |
| Bone scintigraphy | 45 (43%) | 11 (42%) | 0.57 |
| 18FDG-PET | 12 (11%) | 2 (8%) | 0.45 |
GU Genitourinary, GI gastrointestinal, HN head and neck, Gyne Gynecology, SCC squamous cell carcinoma, Adeno adenocarcinoma, Small small cell carcinoma, CC clear cell carcinoma, MRI magnetic resonance imaging, 18FDG-PET 18fluorodeoxyglucose-positron emission tomography